Welcome And The Big Question

Nicolette 0:00

Welcome to the Health Pulse, your go-to source for quick, actionable insights on health, wellness, and diagnostics. Whether you're looking to optimize your well-being or stay informed about the latest in-medical testing, we've got you covered. Join us as we break down key health topics in just minutes. Let's dive in.

Mark 0:24

What

Why ApoB Beats LDL Cholesterol

Mark 0:25

if uh what if the standard cholesterol test you get every single year at your doctor's office is, you know, completely missing the actual biological triggers of heart disease?

Rachel 0:36

Yeah. It's a scary thought.

Mark 0:38

Right. I mean, welcome to the deep dive. We are taking a really hard look at cardiovascular risk today.

Rachel 0:43

Yeah.

Mark 0:44

And if you follow this space, you probably already know that the old paradigm of like good and bad cholesterol is pretty much dead.

Rachel 0:51

Completely dead, yeah.

Mark 0:52

Today, a marker called APOB is the undisputed gold standard for measuring your risk. But we're looking at a brand new article from Quick Lab Mobile, and it breaks down this massive study just published in the European Heart Journal. It's a huge study. It really is. And the mission for our deep dive today is to answer a very specific and honestly somewhat unsettling question. Are all APOB particles equally dangerous?

Rachel 1:15

Because the new data suggests they really aren't.

Mark 1:18

Exactly. Simply counting the number of these particles in your blood is it's barely scratching the surface. So, okay, let's unpack this.

Rachel 1:25

Aaron Powell Right. So to really understand what this European Heart Journal study reveals, we kind of have to establish what APOB is actually doing in the first place.

Mark 1:34

Aaron Powell Right. Set the baseline for us.

Rachel 1:36

Yeah. So APOB or APOLIPO protein B is basically a structural protein. Every single athrogenic lipoprotein particle in your blood.

Mark 1:45

Aaron Powell Meaning the ones capable of causing black, right?

Rachel 1:49

Exactly. The ones that cause the damage. Every single one of them carries exactly one APOB molecule. So when you get an APOB test, you aren't measuring the volume or like the mass of cholesterol in your blood.

SPEAKER_02 2:02

You're getting a headcount.

Rachel 2:03

Yes, precisely. You are getting a precise one-to-one headcount of the individual particles that actually have the potential to penetrate your arterial wall. That is exactly why it's the gold standard.

SPEAKER_02 2:13

Aaron Powell But this new research kind of pushes this past the headcount, doesn't it?

Rachel 2:17

Aaron Powell It does. It forces us to ask, you know, what are these particles actually structurally composed of? And more importantly, what biological chaos do they unleash once they actually breach the vessel wall?

Mark 2:27

Aaron Powell So to conceptualize this for you listening, think of your bloodstream like a highway, right? Old school LDL testing just weighs all the cargo on the road.

Rachel 2:35

Aaron Powell Right, just total mass.

Mark 2:36

Aaron Powell But measuring APO B is actually counting the number of delivery trucks that could potentially crash into the arterial wall. Is that right?

Rachel 2:44

Aaron Ross Powell That is a much more accurate way to view it. The badge or the truck gets them in the door, but the biological payload dictates the actual damage. Aaron Powell Right.

Mark 2:53

And so if APOB counts the trucks, we need to know what kinds of trucks are actually on the road. And the source categorizes these trespassers into three distinct

Three ApoB Particle Families

Mark 3:03

structural families, right?

Rachel 3:04

Aaron Powell Yeah, exactly. Three. So you have particles originating from your intestines, which are called chylomicrons, and they carry a shorter APOB38 badge.

Mark 3:11

Okay, so that's the gut.

Rachel 3:12

Right. But in a fasting state, which is one we usually test, your blood is dominated by the liver-derived particles. And all of these carry the full-length APOB100 badge.

Mark 3:22

Aaron Powell Okay, so ApoB100 is from the liver.

Rachel 3:24

Aaron Powell Exactly. And this includes very low density lipoproteins, or VLDL. It includes intermediate density lipoproteins, or IDL, standard LDL, of course, and a very specific genetic variant called LPA.

Mark 3:37

Aaron Powell Right. Those liver-derived ones are the main focus of this study. And the first family is just standard LDL, which as I understand it is actually just the end product of a life cycle, right? Aaron Ross Powell, Jr.

Rachel 3:47

It is, yeah. The liver packs triglycerides and cholesterol into this massive VLDL particle, basically to deliver energy to your tissues. Trevor Burrus, Jr.

Mark 3:55

It's like a really full cargo truck.

Rachel 3:56

Exactly. And as that VLDL travels through your circulation, it drops off its fat cargo, it shrinks down into an IDL particle, and eventually it metabolizes all the way down into a standard LDL particle.

Mark 4:08

Aaron Powell Which brings us to the second family, which is the triglyceride-rich lipoproteins. This includes that newly minted VLDL we just mentioned, but the article focuses heavily on something called remnants.

Rachel 4:18

Oh, remnants are incredibly insidious.

Mark 4:20

Why is that?

Rachel 4:21

Well, as a VLDL particle drops off its triglycerides, it's supposed to just be cleared from the bloodstream, right? But when clearance is impaired, you are left with these partially depleted, highly condensed particles.

Mark 4:33

So they're smaller.

Rachel 4:34

They're smaller than VLDL, yeah. Meaning they easily slip past the endothelial barrier of your artery, but they are incredibly rich in cholesterol.

Mark 4:42

Okay, I definitely want to come back to why those remnants are so dangerous in a minute. But I want to look at the third family first, which

Lp(a) Genetics And Inflammation

Mark 4:48

is LPA.

Rachel 4:48

Right.

Mark 4:49

The article emphasizes that this one is driven almost entirely by genetics.

Rachel 4:54

Almost 100%, yes.

Mark 4:55

So if you are listening to this right now and you eat perfectly, you exercise daily, you sleep eight hours a night, could you still have a highly elevated risk from LPA?

Rachel 5:06

Without a doubt. You absolutely could. And what's fascinating here is the sheer molecular stubbornness of LPA.

Mark 5:13

Stubbornness. What do you mean by that?

Rachel 5:14

Well, it starts with a standard LDL core, right? Complete with that ACO B100 access badge we talked about. But it has an entirely separate massive protein structure attached to it. It's called apolepoprotein.

Mark 5:25

Okay, so it's LDL with an attachment.

Rachel 5:27

Yeah, and this isn't just loosely associated. It is bound to the LDL core by a rigid disulfide bond.

Mark 5:34

Wow, so it's locked on there.

Rachel 5:35

Exactly. That chemical sulfur bridge makes LPA incredibly stable and highly resistant to being broken down or cleared by your normal liver receptors.

Mark 5:46

The source also mentions Kringle structures on this attached protein weight. Kringle like like the pastry?

Rachel 5:51

Yes, literally like the pastry.

Mark 5:53

Really? What does that actually look like on a molecular level and why does the number of them matter?

Rachel 5:58

So it's named after the Danish pastry because the amino acid sequences literally loop back on themselves in a way that resembles a pretzel or a Kringle under a microscope.

Mark 6:07

That's wild.

Rachel 6:08

It is. But structurally, these loops act like biological velcro.

Mark 6:12

Oh wow.

Rachel 6:13

Yeah. Based on your specific LPA gene, you inherit a certain number of these Kringle repeats. Some people have very few, some have many, but these sticky loops are precisely why LPA binds to the damaged arterial wall so aggressively.

Mark 6:27

Aaron Powell But it's not just getting stuck that makes it dangerous, right? Because the paper node's LPA brings something else into the artery wall with it.

Rachel 6:35

Yes, it brings oxidized phospholipids.

Mark 6:38

Which are what, exactly?

Rachel 6:39

They are these degraded, highly reactive fat molecules that act as a massive irritant to your tissue. So when LPA crashes into the vessel wall, it doesn't just deposit cholesterol, it unleashes these oxidized phospholipids.

Mark 6:53

They're dropping a bomb.

Rachel 6:54

Basically, yeah, and that directly provokes the immune system. This intense localized inflammation is exactly why LPA is a primary driver not just of coronary artery disease, but of calcific aortic valve disease.

Mark 7:07

Wait, it affects the heart valves too.

Rachel 7:09

Oh, absolutely. The tissue gets so inflamed that the body tries to heal it by depositing calcium, which essentially turns a flexible heart valve into rigid bone.

Mark 7:18

Aaron Powell That is terrifying.

Rachel 7:19

It really is.

Mark 7:20

Okay, so LPA is this genetically determined, heavily armed trespass. And we can't currently diet our way out of that one.

Rachel 7:28

Right. Sadly not.

Insulin Resistance And Remnant Particles

Mark 7:29

But let's look at the second family, the triglyceride remnants, because we can heavily influence those through metabolic health, right?

Rachel 7:36

Aaron Ross Powell Oh, absolutely. We have a lot of control there.

Mark 7:38

Aaron Powell Because the source draws this massive straight line between insulin resistance and these remnant particles. Biologically speaking, why does my body's inability to handle carbohydrates suddenly flood my bloodstream with cholesterol remnants?

Rachel 7:53

Well, because we tend to think of insulin solely as a blood sugar regulator, right? But its role in lipid metabolism is honestly just as critical.

SPEAKER_02 8:02

How so?

Rachel 8:03

So in your adipose tissue, your fat cells, insulin acts as a molecular lock. It suppresses lipolysis, basically telling your fat cells to hold on to their stored energy.

Mark 8:13

Okay, it makes sense.

Rachel 8:14

But as you become insulin resistant, your cells become deaf to that signal. The lock breaks.

Mark 8:19

So the fat cells just start leaking.

Rachel 8:20

Exactly. They hemorrhage free fatty acids directly into your circulation, and all those free fatty acids head straight to the liver.

Mark 8:28

So the liver is just getting bombarded.

Rachel 8:29

Yes. It's suddenly overwhelmed with this massive influx of energy, so it panics and it aggressively repackages those fatty acids into triglycerides, shoves them inside VLDL particles, and pumps them back into the blood. And at the exact same time, insulin resistance alters hepatic glucose metabolism, forcing the liver to create even more new fat from scratch.

Mark 8:53

So you've got this massive fleet of VLDL particles just flooding the bloodstream. Yeah. But how did they become the dangerous remnants we talked about earlier?

Rachel 9:01

Right. So that comes down to clearance. As these VLDL particles circulate, there's an enzyme on the lining of your blood vessels called lipoprotein lipase. It's supposed to grab them and unload the triglycerides into your muscles and tissues.

Mark 9:14

But insulin resistance messes that up.

Rachel 9:16

It impairs that enzyme, yes. It gets sluggish.

Mark 9:18

Right.

Rachel 9:18

Furthermore, these particles carry surface proteins. Think of them as molecular barcodes like APOS C3 and APOE.

SPEAKER_02 9:25

No cat codes.

Rachel 9:26

Right. And in an insulin-resistant environment, you get an over-expression of APOS C3, which essentially hides the particle from the liver's clearance receptors.

Mark 9:34

But the normal metabolic machinery completely breaks down.

Rachel 9:37

Completely.

Mark 9:37

The triglycerides are only partially unloaded, the liver can't clear them, and you're just left with this swarm of small, highly concentrated remnant particles.

Rachel 9:46

Yes. And this severely distorts your standard lipid panel. You develop high triglycerides and low HDL, but your standard LDLC mass might actually look perfectly normal.

Mark 9:57

Hold on, I really want to underline this for the listener. You could get your annual lab results back, right? And your doctor says your LDLC is in the safe zone, but underneath, you are actually harboring a massive concentration of these tiny cholesterol depleted remnant particles.

Rachel 10:14

Yes. That happens all the time.

Mark 10:16

That's crazy.

Rachel 10:17

It's because the total volume of cholesterol inside the particles might be low, making your LDLC mass look acceptable. But the APUB B head count, the actual number of particles capable of breaching the arterial wall is wildly elevated.

Mark 10:29

Right, because there's just so many of these little remnants.

Rachel 10:31

Exactly. And because these remnants are prone to oxidation and they carry their own inflammatory barcode proteins, your actual cardiovascular risk is severely underestimated by those standard tests.

The Proteomic Fingerprints Study

Mark 10:42

Which perfectly bridges us to the actual European Heart Journal study. We know these three families, LDL, LPA, and triglyceride remnants. We know they're structurally different. Right. But the researchers didn't want to just look at their physical shapes. They wanted to see the chemical trail they leave in the blood.

Rachel 10:59

The biological environment.

Mark 11:00

Yeah. So they analyzed over 35,000 participants in the UK Biobank, and then they validated it in another 5,900 people from the multi-ethnic study of atherosclerosis. But they weren't measuring cholesterol, right? They were measuring, what was it, 2,918 different plasma proteins.

Rachel 11:19

Yeah, almost 3,000 proteins. It was an unprecedented look at the biological environment. They were searching for the proteomic fingerprint of each particle family.

Mark 11:28

Like what alarms are they setting off?

Rachel 11:29

Exactly. If these particles are causing damage, what systemic alarms are they tripping in the body?

Mark 11:34

Here's where it gets really interesting. The disparity in the result is shocking. When they isolated standard LDL, it was significantly associated with only 30 proteins. So 30. Right. LPA was associated with 53 proteins. But the triglyceride-rich lipoproteins, they were associated with 471 different proteins.

Rachel 11:56

Yeah, the magnitude of that difference, I mean, it cannot be overstated. A 471 protein signature means that triglyceride remnants aren't just passively floating in the blood, you know.

Mark 12:06

They're doing something.

Rachel 12:07

They are actively engaging with the immune system and the vascular tissue.

Mark 12:11

And the study highlights a significant overlap, right? Because the triglyceride remnants and the LPA particles shared 36 specific proteins. What are those proteins actually doing?

Rachel 12:22

Right. So those 36 are heavily enriched in pathways driving immune activation and vascular remodeling.

Mark 12:27

Vascular remodeling. That sounds bad.

Rachel 12:29

It is. When we say vascular remodeling, we mean the structural cells of your blood vessels, the smooth muscle cells. They are chemically instructed to change their shape, to multiply, and lay down fibrous tissue.

Mark 12:40

Basically making the artery stiffer.

Rachel 12:42

Exactly. And the immune activation is largely driven by chemokines, which act as a distress beacon, calling in macrophages.

Mark 12:48

The immune system's cleanup crew.

Rachel 12:50

Right. But these macrophages dive into the arterial wall, they gorge themselves on the oxidized lipids from the remnants and the LPA, and they become what we call foam cells.

Mark 13:01

Aaron Powell And those form the plaque, right?

Rachel 13:03

Exactly. They form the necrotic core of a plaque.

Mark 13:06

So these particles are effectively orchestrating their own plaque buildup by weaponizing the body's immune response.

Rachel 13:12

Aaron Powell That's a great way to put it. Yeah.

Mark 13:14

And the researchers use something called mediation modeling to quantify this, didn't they? Can you explain what mediation modeling actually does here?

Rachel 13:22

Yeah. So mediation modeling is a statistical method used to trace the chain of causality.

Nicolette 13:27

Okay.

Rachel 13:28

Rather than just saying, you know, high remnants equal heart attacks, mediation modeling asks how much of that heart attack risk mathematically passes through these specific inflammatory proteins.

Mark 13:39

Got it. And what do they find?

Rachel 13:40

The findings were profound. They estimated that about 14% of the coronary risk from LPA is mediated by these proteomic alterations.

Mark 13:49

Okay, 14%.

Rachel 13:50

But for the triglyceride-rich remnants, a staggering 62% of their coronary risk is mediated by these inflammatory and immune proteins.

Mark 13:59

62%.

Rachel 14:00

Yeah.

Mark 14:00

That implies the vast majority of the danger for metabolic dysfunction isn't just the cholesterol itself, it's the massive biological fire it starts in the bloodstream.

Rachel 14:09

Exactly.

LDL As The Silent Killer

Mark 14:10

But wait, I have to push back on the LDL data for a second. If LDL only triggered 30 proteins, and the study noted its protein score wasn't independently associated with coronary events after adjustments. I mean, have we been wrong this whole time? Are you saying plain old LDL is effectively harmless?

Rachel 14:27

Okay, so if we connect this to the bigger picture, it is absolutely vital that we don't draw that conclusion.

SPEAKER_02 14:32

Okay, good.

Rachel 14:32

LDL is absolutely lethal, but its mechanism of lethality is different. The lack of a massive proteomic signature simply means LDL is a silent killer.

Mark 14:42

Explain that. If it's lethal, why isn't the body sounding the alarm?

Rachel 14:45

Aaron Powell Because standard LDL mostly exerts its harm through a slow, cumulative, localized physical process.

Mark 14:51

Like it just builds up over time.

Rachel 14:53

Right. It slips into the artery wall and gets retained. It doesn't carry the highly reactive oxidized phospholipids of LPA, and it doesn't carry the inflammatory EPOS-3 surface proteins of the triglyceride remnants. So it doesn't trigger 471 systemic alarms in your circulating plasma. But over decades, that localized physical accumulation builds plaque, it narrows the artery, and eventually it ruptures.

Mark 15:18

So LDL operates under the radar while the other two are screaming through a megaphone.

Rachel 15:23

Exactly. But all three end in cardiovascular events.

Mark 15:26

That clarifies a massive potential misunderstanding. So moving

A Smarter Testing Stack

Mark 15:30

from this incredibly detailed biology into practical application, how do you, the listener, actually use this to assess your own health? If APOW is the ultimate headcount, how do we capture both the number of trespassers and the biological weapons they're carrying?

Rachel 15:44

Well, you have to build a comprehensive testing stack. First off, you do not abandon APOB. APOB remains the absolute best metric to define your exposion opportunity.

Mark 15:52

Right, the head count.

Rachel 15:53

It tells you exactly how many particles are capable of entering the arterial wall, but you must contextualize that number.

Mark 15:59

Aaron Powell So what exactly is in this stack?

Rachel 16:01

You start with a standard lipid panel, you know, LDLC, triglycerides, HDLC. From there, your physician can calculate your non-HDL cholesterol, which basically encompasses the cholesterol mass of all APOB particles.

SPEAKER_02 16:14

Got it.

Rachel 16:15

They can also estimate your remnant cholesterol, giving you a real sense of the burden from those triglyceride-rich particles.

Mark 16:22

And what about LPA? Can we just deduce that from the APOB count?

Rachel 16:25

No. And this is a critical clinical trap.

Mark 16:28

Really?

Rachel 16:28

Yeah. Two patients could have an identical APOB score of 90, right? One might have virtually zero LPA, while the other has a massive genetically driven concentration that fundamentally changes their risk profile and their treatment timeline.

Mark 16:42

Oh wow. So you have to measure it separately.

Rachel 16:44

LPA must be measured directly via a specific blood test. And for the listener looking at their labs, notice if your LPA is reported in milligrams per deciliter, which measures mass, or nanomoles per liter, which measures particle count.

Mark 16:57

Can't you just use a math formula to convert one to the other?

Rachel 17:00

You mathematically cannot.

Mark 17:02

Wait, really? Why not?

Rachel 17:03

Because, as we discussed, the isoform, the physical structure of the LPA particle, varies wildly from person to person based on how many of those Kringle loops they inherited?

Mark 17:13

Right, the Velcro loops.

Rachel 17:15

Exactly. You can't use a universal conversion factor because you'd be assuming everyone's LPA molecule weighs exactly the same, which is genetically false.

Mark 17:23

Good to know. So what does this all mean for our metabolic context? If I have my APOB, my standard panel, and my LPA direct measurement, is the picture complete?

Rachel 17:33

Not if you want to understand if you are fueling that 471 protein fire we talked about. You have to measure the metabolic environment. That means testing fasting insulin, not just fasting glucose. You need your HBA1C, a look at your triglyceride to HDL ratio to assess insulin sensitivity.

Mark 17:51

And inflammation markers, too.

Rachel 17:52

Ideally, yes. An inflammatory marker like HSCRP to see if your body is already in a state of systemic immune distress.

Mark 17:59

This raises an important question, though, doesn't it? Like as medicine evolves, are we just treating a lipid number on a lab report, or do we have to start treating the entire biological environment of the patient?

Rachel 18:09

Well, that is the exact paradigm shift the European heart journal study represents. You do not have to choose between managing the particle number and managing the particle biology. A neat bowl. Exactly. APOB establishes the baseline opportunity for disease. But the specific particle type, be it an oxidized LPA particle or a metabolically deranged triglyceride remnant, along with the surrounding metabolic dysfunction, dictates exactly how that exposure accelerates into physical heart disease.

Mark 18:38

So to synthesize this entire journey for you today, APOW B is undeniably the ultimate headcount of the dangerous particles in your blood. But knowing exactly who is in that crowd, you know, whether it's genetically engineered LPA armed with oxidized phospholipids, or metabolically driven triglyceride remnants weaponizing your immune system, that's the key to understanding your true risk.

Rachel 19:01

That's spot on.

Mark 19:02

It is not just about the number of access badges, it is about what those particles are chemically programmed to do once they breach the arterial wall.

Rachel 19:10

The precision of the science is staggering, really, and it allows us to move away from guesswork and directly target the root biological mechanisms

The Future Of Personalized Prevention

Rachel 19:18

of risk.

Mark 19:18

Which leaves me with a final, somewhat provocative thought for you to explore on your own. If LPA is purely genetic and stubbornly ignores lifestyle changes, and triglyceride remnants are heavily tied to insulin resistance and how your specific body handles carbohydrates, are we rapidly approaching a future where a generalized heart-healthy diet is completely obsolete?

Rachel 19:41

That's a great question. Right.

Mark 19:42

Like if we can identify your unique proteomic fingerprint, will we soon be treating cardiovascular risk by manipulating individual immune proteins and pathways, essentially stopping heart disease years before a plaque even has the physiological chance to form?

Rachel 19:56

That is exactly the frontier of preventative cardiology.

Mark 19:59

It really makes the old binary view of cholesterol look incredibly primitive. The murky waters of cardiovascular diagnostics are finally starting to clear. Thank you so much for joining us on this deep dive. Keep questioning the consensus, keep looking past the standard lipid panel, and keep seeking out the why behind your health.

Nicolette 20:16

We'll see you next time.quickLabmobile.com. Stay informed, stay healthy, and we'll catch you in the next episode.